Switzerland Reopens the Phage Therapy Debate as Antibiotic Resistance Continues to Rise

-

As antibiotic resistance continues to challenge healthcare systems worldwide, Switzerland is increasingly re-evaluating the role bacteriophage therapy could play in the treatment of difficult bacterial infections. On May 30, 2026, researchers, physicians, regulators, biotechnology companies, and patient advocates will gather in Lausanne for the Forum Phagothérapie, a public event dedicated to the scientific, clinical, and regulatory future of phage therapy in Switzerland.

Register here : https://phagenforum.ch/fr/events/

Phagen Forum ©

The event comes at a time when multidrug-resistant infections are becoming increasingly difficult to manage with conventional antibiotics alone. Although antibiotics remain one of the most important tools in modern medicine, bacterial resistance continues to accelerate across hospitals and community healthcare systems. In Switzerland, as in many other countries, some patients suffering from chronic or recurrent infections are running out of effective therapeutic options.

Bacteriophages, viruses that specifically infect and destroy bacteria, are attracting renewed scientific attention because of their ability to selectively target pathogenic bacteria while preserving surrounding microbiota. Unlike broad-spectrum antibiotics, phages can adapt alongside evolving bacterial populations and may also penetrate bacterial biofilms that are often highly resistant to antimicrobial treatment.

Despite growing international interest, phage therapy remains highly restricted in Switzerland and is currently permitted mainly in exceptional or compassionate-use situations. Organizers of the Lausanne forum aim to open discussion around whether access to these therapies should become more flexible, particularly for patients affected by severe multidrug-resistant infections.

The forum will bring together several major actors involved in Swiss phage research and regulation, including clinicians from Lausanne University Hospital, specialists in therapeutic phage production, legal experts in medical ethics, representatives connected to Swissmedic, biotechnology entrepreneurs, and patient advocates directly affected by chronic antibiotic-resistant infections. Discussions will address topics such as manufacturing standards, personalized phage therapy, regulatory approval pathways, and the scientific challenges associated with integrating phages into modern clinical medicine.

Several clinical situations associated with antimicrobial resistance will also be highlighted during the event, including diabetic foot infections, chronic respiratory infections linked to cystic fibrosis, implant-associated infections, recurrent urinary tract infections, and bacterial complications in immunocompromised cancer patients. Many of these infections are complicated by bacterial biofilms, which dramatically reduce antibiotic efficacy and contribute to long-term treatment failure.

Beyond its scientific dimension, the Lausanne initiative reflects a broader societal debate surrounding the future of infectious disease treatment. Public health authorities continue to warn that antimicrobial resistance could become one of the leading causes of global mortality in the coming decades if alternative therapeutic approaches fail to emerge.

As phage therapy continues to evolve from experimental medicine toward structured clinical development, events such as the Forum Phagothérapie illustrate how Europe is gradually beginning to integrate bacteriophages into larger conversations surrounding precision medicine, microbiology, and the future of antimicrobial innovation.

Source : https://phagenforum.ch/fr/events/

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more